(2R,4S,5S)-4-Azido-5-(3-dipropylcarbamoyl-benzoylamino)-2,7-dimethyl-octanoic acid | 637024-85-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R,4S,5S)-4-Azido-5-(3-dipropylcarbamoyl-benzoylamino)-2,7-dimethyl-octanoic acid
• 英文别名: (2R,4S,5S)-4-azido-5-[[3-(dipropylcarbamoyl)benzoyl]amino]-2,7-dimethyloctanoic acid
• CAS: 637024-85-2
• 化学式: C₂₄H₃₇N₅O₄
• 分子量: 459.589
• InChiKey: NFQSERZCENDHPZ-QMMLZNLJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  33
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2R,4S,5S)-4-Azido-5-(3-dipropylcarbamoyl-benzoylamino)-2,7-dimethyl-octanoic acid 在 palladium on activated charcoal 氢气 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[(1S,2S,4R)-2-Amino-4-((S)-1-benzylcarbamoyl-2-methyl-propylcarbamoyl)-1-isobutyl-pentyl]-N',N'-dipropyl-isophthalamide
  参考文献：
  名称：

  Aminoethylenes:  A Tetrahedral Intermediate Isostere Yielding Potent Inhibitors of the Aspartyl Protease BACE-1

  摘要：

  A series of novel beta-site amyloid precursor protein cleaving enzyme (BACE-1) inhibitors containing an aminoethylene (AE) tetrahedral intermediate isostere were synthesized and evaluated in comparison to corresponding hydroxyethylene (HE) compounds. Enzymatic inhibitory values were similar for both isosteres, as were structure-activity relationships with respect to stereochemical preference and substituent variation (P2/P3, P1, and P2'); however, the AE compounds were markedly more potent in a cell-based assay for reduction of beta-secretase activity. The incorporation of preferred P2/ P3, P1, and P2' substituents into the AE pharmacophore yielded compound 7, which possessed enzymatic and cell assay IC(50)s of 26 nM and 180 nM, respectively. A three-dimensional crystal structure of 7 in complex with BACE-1 revealed that the amino group of the inhibitor core engages the catalytic aspartates in a manner analogous to hydroxyl groups in HE inhibitors. The AE isostere class represents a promising advance in the development of BACE-1 inhibitors.

  DOI：

  10.1021/jm0509142
• 作为产物：
  描述：

  dimethyl <(3S)-5-methyl-3-<(tert-butoxycarbonyl)amino>-2-oxohexyl>phosphonate 在 palladium on activated charcoal 咪唑 、 盐酸 、 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 正丁基锂 、 sodium azide 、 jones' reagent 、 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙二醇二甲醚 、 二氯甲烷 、 氯仿 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成 (2R,4S,5S)-4-Azido-5-(3-dipropylcarbamoyl-benzoylamino)-2,7-dimethyl-octanoic acid
  参考文献：
  名称：

  Aminoethylenes:  A Tetrahedral Intermediate Isostere Yielding Potent Inhibitors of the Aspartyl Protease BACE-1

  摘要：

  A series of novel beta-site amyloid precursor protein cleaving enzyme (BACE-1) inhibitors containing an aminoethylene (AE) tetrahedral intermediate isostere were synthesized and evaluated in comparison to corresponding hydroxyethylene (HE) compounds. Enzymatic inhibitory values were similar for both isosteres, as were structure-activity relationships with respect to stereochemical preference and substituent variation (P2/P3, P1, and P2'); however, the AE compounds were markedly more potent in a cell-based assay for reduction of beta-secretase activity. The incorporation of preferred P2/ P3, P1, and P2' substituents into the AE pharmacophore yielded compound 7, which possessed enzymatic and cell assay IC(50)s of 26 nM and 180 nM, respectively. A three-dimensional crystal structure of 7 in complex with BACE-1 revealed that the amino group of the inhibitor core engages the catalytic aspartates in a manner analogous to hydroxyl groups in HE inhibitors. The AE isostere class represents a promising advance in the development of BACE-1 inhibitors.

  DOI：

  10.1021/jm0509142

文献信息

• Aspartyl protease inhibitors
  申请人：——

  公开号：US20040147454A1

  公开（公告）日：2004-07-29

  The present invention provides compounds having the formula: 1 wherein R 1 , R′, R 2 , R 3 , R 3′ , R 4 , X 1 , X 2 and X 3 are as defined herein, and pharmaceutical compositions thereof. The present invention also provides methods of inhibiting proteases, more specifically aspartyl proteases. In certain embodiments, compounds inhibit BACE (&bgr;-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by &bgr;-amyloid deposits in the brain (including, but not limited to, Alzheimer's Disease). The present invention also provides methods for preparing compounds of the invention.

  本发明提供具有以下公式的化合物：1其中R1、R′、R2、R3、R3′、R4、X1、X2和X3如本文所定义，以及其药物组合物。本发明还提供抑制蛋白酶的方法，更具体地是抑制天冬氨酸蛋白酶。在某些实施方式中，这些化合物抑制BACE（β-APP剪切酶），因此在治疗或预防大脑中存在β-淀粉样沉积的疾病（包括但不限于阿尔茨海默病）方面是有用的。本发明还提供制备本发明化合物的方法。
• [EN] ASPARTYL PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ASPARTYL-PROTEASE
  申请人：SUNESIS PHARMACEUTICALS INC

  公开号：WO2003106405A1

  公开（公告）日：2003-12-24

  The present invention provides compounds having formula (I): wherein R’, R0, R1, X1, R2, R3, R3’, X2, X3, and R4 are as defined herein, and pharmaceuticals compositions thereof. The present invention also provides methods of inhibiting proteases, more specially aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer’s Disease). The present invention also provides methods for preparing compounds of the invention.

  本发明提供具有以下结构的化合物（I）：其中R'、R0、R1、X1、R2、R3、R3'、X2、X3和R4如本文所定义，并且其药物组合物。本发明还提供抑制蛋白酶的方法，更具体地是天冬氨酸蛋白酶。在某些实施例中，这些化合物抑制BACE（β-APP裂解酶），因此可用于治疗或预防大脑中存在β-淀粉样沉积的疾病（包括但不限于阿尔茨海默病）。本发明还提供了制备本发明化合物的方法。
• Aminoethylenes:  A Tetrahedral Intermediate Isostere Yielding Potent Inhibitors of the Aspartyl Protease BACE-1
  作者：Wenjin Yang、Wanli Lu、Yafan Lu、Min Zhong、Jian Sun、Anila E. Thomas、Jennifer M. Wilkinson、Raymond V. Fucini、Melissa Lam、Mike Randal、Xiao-Ping Shi、Jeffrey W. Jacobs、Robert S. McDowell、Eric M. Gordon、Marcus D. Ballinger

  DOI：10.1021/jm0509142

  日期：2006.2.1

  A series of novel beta-site amyloid precursor protein cleaving enzyme (BACE-1) inhibitors containing an aminoethylene (AE) tetrahedral intermediate isostere were synthesized and evaluated in comparison to corresponding hydroxyethylene (HE) compounds. Enzymatic inhibitory values were similar for both isosteres, as were structure-activity relationships with respect to stereochemical preference and substituent variation (P2/P3, P1, and P2'); however, the AE compounds were markedly more potent in a cell-based assay for reduction of beta-secretase activity. The incorporation of preferred P2/ P3, P1, and P2' substituents into the AE pharmacophore yielded compound 7, which possessed enzymatic and cell assay IC(50)s of 26 nM and 180 nM, respectively. A three-dimensional crystal structure of 7 in complex with BACE-1 revealed that the amino group of the inhibitor core engages the catalytic aspartates in a manner analogous to hydroxyl groups in HE inhibitors. The AE isostere class represents a promising advance in the development of BACE-1 inhibitors.